Organon
Organon & Co.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$6.2B
Operating marginCalculated
Could not be retrieved
Net assets to total assetsCalculated
5.8%
Company profile
Tables scroll sideways
Disclosed data
Profitability
Could not be retrieved
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-0.4%
Capital efficiency
★★★★☆position among all companies
24.9%
Revenue and profit
Performance, financial position and capital allocation
Organon
Recent performance trends
Organon
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$6.3 billion | US$6.2 billion | US$6.3 billion | US$6.4 billion | US$6.2 billion |
| Net income | US$1.4 billion | US$0.9 billion | US$1.0 billion | US$0.9 billion | US$0.2 billion |
| Total assets | US$10.7 billion | US$11.0 billion | US$12.1 billion | US$13.1 billion | US$12.9 billion |
| Shareholders' equity | US$-1.5 billion | US$-0.9 billion | US$-70.00 million | US$0.5 billion | US$0.8 billion |
| Net cash provided by (used in) operating activities | Could not be retrieved | US$0.9 billion | US$0.8 billion | US$0.9 billion | US$0.7 billion |
| Net cash provided by (used in) investing activities | Could not be retrieved | US$-0.4 billion | US$-0.3 billion | US$-0.5 billion | US$-0.4 billion |
| Net cash provided by (used in) financing activities | Could not be retrieved | US$-0.4 billion | US$-0.6 billion | US$-0.4 billion | US$-0.6 billion |
| Cash and cash equivalents | US$0.7 billion | US$0.7 billion | US$0.7 billion | US$0.7 billion | US$0.6 billion |
Revenue scale in the same industry
Organon
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 29 companies
- 33 Dupont DE NemoursFY Dec 2025 US$6.8B
- 34 OlinFY Dec 2025 US$6.8B
- 35 OrganonThis companyFY Dec 2025 US$6.2B
- 36 Church & Dwight COFY Dec 2025 US$6.2B
- 37 The ChemoursFY Dec 2025 US$5.8B
- … 19 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.2 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.7 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.2 billion | Consolidated | Disclosed |
| Dividends paid | US$88.00 million | Consolidated | Disclosed |
| Net assets | US$0.8 billion | Consolidated | Disclosed |
| Net sales | US$6.2 billion | Consolidated | Disclosed |
| Net income | US$0.2 billion | Consolidated | Disclosed |
| Total assets | US$12.9 billion | Consolidated | Disclosed |
| Operating margin | Cannot be calculated | Not applicable | Not calculated (no operating income in this year's 10-K) |
| Net assets to total assets | 5.8% | Consolidated | Calculated |
| Net margin | 3.0% | Consolidated | Calculated |
| Return on equity | 24.9% | Consolidated | Calculated |